Avacta Group (AIM: AVCT) claims preCISION payload delivery shows structural advantages over ADCs as AVA6103 nears clinic

Avacta Group plc (AIM: AVCT) has released new preclinical and AI-driven comparative data indicating that its preCISION tumor-activated payload delivery platform may offer meaningful pharmacokinetic and selectivity advantages over antibody drug conjugates, positioning its FAP-Exd candidate AVA6103 for clinical entry in early 2026. The disclosure matters because it directly challenges the prevailing ADC delivery paradigm at a time when payload efficiency, tumor penetration, and tolerability are becoming binding constraints on oncology drug development.

Why Avacta Group plc is attacking the antibody drug conjugate model rather than competing within it

The antibody drug conjugate class has delivered undeniable clinical and commercial wins, but its limitations are increasingly visible at scale. ADCs are large biologic constructs that depend on target receptor binding, internalization, linker cleavage, and intracellular release to deliver cytotoxic payloads. Each step introduces inefficiency, heterogeneity, and systemic exposure risk.

Avacta Group plc is not positioning preCISION as an incremental ADC improvement. It is arguing that the entire delivery architecture can be simplified by removing the antibody component altogether and relying instead on tumor-specific protease activation within the tumor microenvironment. The preCISION platform uses fibroblast activation protein as the gating mechanism, a protease broadly upregulated across solid tumors and largely absent from healthy tissue.

This distinction matters strategically. ADC innovation has increasingly revolved around linker chemistry and payload potency, while the delivery vehicle itself has remained largely unchanged. Avacta Group plc is effectively questioning whether antibodies are the optimal delivery vehicle at all when tumor-activated small-molecule conjugates can achieve faster penetration and higher local exposure with lower systemic spillover.

How the AI-generated synthetic comparator reframes the Enhertu benchmark discussion

One of the more consequential aspects of the disclosure is not the raw data itself but the methodological approach. Avacta Group plc used artificial intelligence to reconstruct a synthetic comparator arm based on published AstraZeneca data for trastuzumab deruxtecan, allowing a direct comparison without replicating the original experiments.

This approach serves two purposes. First, it enables a head-to-head pharmacokinetic comparison against one of the most successful ADCs in oncology without introducing experimental variability from parallel in-house studies. Second, it signals to regulators, partners, and investors that Avacta Group plc is willing to embrace computational tools to accelerate translational decision-making rather than relying solely on traditional wet-lab repetition.

The use of an AI-derived comparator also implicitly reframes the discussion away from target biology differences, such as HER2 versus FAP, and toward delivery mechanics. Both agents use related topoisomerase I inhibitor payloads, making delivery efficiency the central variable under examination rather than cytotoxic class effects.

What the pharmacokinetic data suggests about tumor penetration speed and payload efficiency

The most striking reported difference lies in delivery kinetics. According to the analysis, AVA6103 achieves maximal tumor payload concentration within minutes of dosing, whereas trastuzumab deruxtecan reaches peak tumor concentration at approximately 24 hours.

From an execution standpoint, this is not a trivial distinction. Rapid tumor penetration suggests that payload release is occurring in the extracellular tumor microenvironment rather than relying on cellular internalization and intracellular processing. That has implications for heterogeneous tumors, poorly vascularized lesions, and cancers with variable antigen expression.

The reported one-log higher absolute tumor Cmax further suggests that preCISION delivery may overcome one of the central bottlenecks of ADCs: dilution of payload across systemic compartments before sufficient tumor accumulation occurs. If borne out clinically, this could enable lower total dosing while achieving higher intratumoral exposure, a long-standing goal in cytotoxic oncology.

Why tumor selectivity index may matter more than peak concentration alone

While peak concentration often attracts headlines, the tumor selectivity index may be the more strategically important metric. Avacta Group plc reports a nearly three-fold higher tumor selectivity index for AVA6103 compared with trastuzumab deruxtecan, defined as the ratio of tumor to plasma exposure over fourteen days.

This metric directly speaks to the therapeutic window. A higher tumor selectivity index implies that efficacy gains are not being purchased at the expense of systemic toxicity. In an ADC landscape increasingly constrained by hematologic toxicity, interstitial lung disease risk, and dose-limiting adverse events, improved selectivity could translate into more durable dosing, broader patient eligibility, and combination flexibility.

For regulators, tumor selectivity also intersects with safety margins and long-term tolerability, particularly as oncology treatment durations extend beyond short induction regimens.

What the animal efficacy signals imply about low antigen and low FAP expression tumors

Beyond pharmacokinetics, Avacta Group plc highlights efficacy data suggesting that AVA6103 retains activity even in tumor models with low FAP expression, while trastuzumab deruxtecan demonstrates variable performance at low HER2 expression levels.

This point deserves attention because antigen heterogeneity has become a major challenge for ADC expansion beyond narrowly defined biomarker-positive populations. If preCISION activation relies on stromal protease activity rather than tumor cell surface antigen density, it may enable a broader therapeutic footprint across solid tumors that have historically been difficult to target with ADCs.

The reported deep and durable responses after only three doses in animal models further reinforce the possibility that delivery efficiency rather than dosing intensity is driving antitumor activity. However, this durability claim remains preclinical and will require cautious interpretation until human data emerges.

How AVA6103 fits into Avacta Group plc’s broader capital and platform strategy

The timing of this data release is not accidental. Avacta Group plc has cash runway into the third quarter of 2026 and is approaching multiple value inflection points across its pipeline. AVA6103 is expected to enter Phase 1 clinical testing in the first quarter of 2026, with preliminary data anticipated in the second half of the year.

Importantly, management has stated an intention to retain full ownership of AVA6103 through early clinical readouts rather than partnering prematurely. This suggests confidence that early human data could materially re-rate the asset and strengthen negotiating leverage.

The preCISION platform is also being extended into dual payload constructs, which could further differentiate Avacta Group plc from ADC-focused competitors by enabling combination mechanisms within a single small-molecule conjugate.

What early clinical validation of AVA6103 could mean for investor sentiment, valuation risk, and Avacta Group plc’s funding outlook

From an investor perspective, Avacta Group plc remains a high-risk, high-conviction clinical-stage story. The company has raised significant equity capital to fund its programs and has deliberately concentrated its value proposition around platform differentiation rather than incremental asset progression.

The Enhertu comparison is strategically astute because it anchors the narrative to a clinically validated benchmark. At the same time, it raises the bar for execution. Any divergence between preclinical promise and early clinical safety or efficacy signals could weigh heavily on sentiment.

That said, the convergence of AI-enabled translational analysis, tumor-activated delivery, and small-molecule manufacturing economics may resonate with institutional investors seeking alternatives to capital-intensive biologic platforms.

What happens next as AVA6103 enters human testing

The immediate next catalyst is regulatory clearance and first patient dosing in the AVA6103 Phase 1 trial, which will enroll multiple solid tumor types selected using AI-driven sensitivity modeling. The trial design emphasizes rapid dose optimization and early signal detection.

If early pharmacokinetic and safety data mirror preclinical selectivity trends, Avacta Group plc could quickly find itself in partnership discussions from a position of relative strength. Conversely, any indication that rapid tumor penetration comes at the expense of off-target exposure would challenge the platform’s core thesis.

Either way, the transition from computational and animal models into human biology will determine whether preCISION represents a genuine delivery paradigm shift or a compelling but niche alternative.

Key takeaways on what Avacta Group plc’s preCISION data means for oncology delivery platforms

• Avacta Group plc is positioning preCISION as a structural alternative to antibody drug conjugates rather than an incremental improvement
• The AI-generated synthetic comparator enables a direct delivery-focused comparison with trastuzumab deruxtecan without experimental duplication
• Faster tumor penetration and higher intratumoral payload concentration suggest a fundamentally different release mechanism
• A higher tumor selectivity index may translate into a wider therapeutic window and improved tolerability
• Activity in low-expression tumor models could expand addressable patient populations beyond biomarker-restricted ADC use
• AVA6103’s imminent clinical entry represents a critical validation point for the preCISION platform
• Retaining full ownership through early data readouts signals management confidence but concentrates execution risk
• Success would strengthen Avacta Group plc’s negotiating leverage with potential partners
• Failure would raise questions about whether delivery efficiency gains can be maintained in humans
• The broader implication is growing investor appetite for delivery innovation beyond traditional biologics